No retraction, correction or concern found when last checked on Oct 26, 2026.

Chronic granulomatous disease: a review of the infectious and inflammatory complications

EunKyung Song, Gayatri Bala Jaishankar, Hana Saleh and 3 more

Clinical and Molecular Allergy · 2011 · Review

Abstract

Chronic Granulomatous Disease is the most commonly encountered immunodeficiency involving the phagocyte, and is characterized by repeated infections with bacterial and fungal pathogens, as well as the formation of granulomas in tissue. The disease is the result of a disorder of the NADPH oxidase system, culminating in an inability of the phagocyte to generate superoxide, leading to the defective killing of pathogenic organisms. This can lead to infections with Staphylococcus aureus , Psedomonas species, Nocardia species, and fungi (such as Aspergillus species and Candida albicans ). Involvement of vital or large organs can contribute to morbidity and/or mortality in the affected patients. Major advances have occurred in the diagnosis and treatment of this disease, with the potential for gene therapy or stem cell transplantation looming on the horizon.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Primary immune deficiencies often present as recurrent infections, often with unusual pathogens, or infections of unusual severity or frequency. Host defense consists of either nonspecific or specific mechanisms of immunity to invading pathogens (Table 1). Nonspecific mechanisms include barrier functions of skin and mucosa (tears, saliva, mucosal secretions, mucociliary responses, and clearance by peristalsis as occurs in the bladder or the gastro-intestinal system), phagocyte responses (neutrophils, macrophages or mononuclear cells and their component of pathogen recognition receptors or PRR and cell adhesion molecules or CAMs), complement system of proteins, C reactive protein (CRP), cytokines, and the PRRs mentioned earlier on the surface of a variety of cell types. Specific immune responses include immunoglobulin class switching and secretion by B lymphocytes/plasma cells and T lymphocyte responses (including antigen recognition, clonal proliferation, and cytokine synthesis resulting in B cell and phagocyte activation and survival).

2Innate immunity occurs rapidly and is relatively nonspecific, while adaptive responses occur later and are characterized by activation of the T and B lymphocytes, antigen recognition, cognate interaction using several key cell surface receptors (discussed later) and the synthesis and secretion of antibodies, cytokines and other effector molecules that lead to an expansion of the specific immune response towards a pathogen (Table 2). There are close interactions between the nonspecific/innate and adaptive immune responses, such that a two-way response as well as independent responses regulate overall immune function. To further add a complex dimension to this process is the recent discovery and description of several regulatory T cell subsets including the T regulatory (T reg/Tr1 and Th3 subset) and the Th17 subset of lymphocytes that oversee overall immune function. The description of these aspects is beyond the scope of this review but needs to be mentioned in order to understand phagocyte function and defects in CGD.

3Primary immune deficiencies can involve either the adaptive (T- and B-lymphocyte deficiencies) or the innate (phagocyte, complement, or other defects) immune response (Table 2). Of these, defects in phagocyte function constitute only about 18%, with the larger portion of the defects seen in the B cell/antibody and/or T cell components of immunity (Figure 1). These various defects are summarized in Figure 2, which describes the potential sequence of events, starting from T- and B cell interactions and antibody synthesis to the involvement of phagocyte and complement components of the innate immune response. Based on the location of a given immune defect, susceptibility to a particular set of pathogens is likely to occur, which can be explained on the basis of the dominant immune response to any specific pathogen. These aspects are summarized in Table 3.

4Disorders of the innate immune system involve defects in complement as well as defective phagocyte responses to infectious illness. In the latter group are a host of disorders, which are summarized in Table 4. These include chronic granulomatous disease (CGD), neutrophil adhesion defects (such as the leukocyte adhesion deficiency syndromes), Chediak-Higashi syndrome, Griscelli syndrome, Kostmann's syndrome, WHIM syndrome (disorder characterized by myelokathexis), mannose binding lectin deficiency (MBL deficiency), and enzymatic defects within phagocytes such as deficiencies of glucose-6-phosphate dehydrogenase (G6PD), glutathione reductase, glutathione synthetase, and myeloperoxidase. CGD is the most commonly encountered disorder of phagocytes, and is characterized be repeated infections with bacterial and fungal pathogens, as well as the formation of granulomas in tissue. The disease is a disorder of the NADPH oxidase system, culminating in an inability of the phagocyte to generate superoxide, leading to the defective killing of pathogenic organisms. As shown in Table 3, defects in phagocyte function lead to infections with Staphylococcus aureus, Psedomonas species, Nocardia species and fungi (such as Aspergillus species and Candida albicans). Due to involvement of vital or large organs, such infections can lead to significant morbidity and/or mortality in the affected patients.

5The following sections discuss the immunobiology of phagocytes, the defects in CGD and the resulting clinical spectrum observed.

Normal Phagocyte Physiology

6Phagocytes include the neutrophils, monocytes, and macrophages. Much of the early understanding of phagocyte biology resulted from the work of Paul Ehrlich and Metchnikov, pioneers who developed staining techniques and methods to study these cells in vitro. The term phagocytosis was probably introduced by Metchnikov. Hematopoietic growth factors such as GM-CSF and M-CSF regulate phagocyte production from the bone marrow, allowing the development of the monocyte-macrophage lineage cell from the CFU-GM, shown in Figure 3. The macrophage serves pleiotropic roles in the immune response, including presenting microbial antigen to the T cells in the context of major histocompatibility complex, a phenomenon referred to as haplotype restriction. T cells, especially the Th1 type cells, secrete interferon gamma (IFN γ) which activates macrophages, which in turn express IL-12 and IL-18, thereby allowing the proliferation of Th1 lymphocytes. Macrophage activation results in the activation of several processes, aided partly by cognate T-macrophage interaction and also by the PRRs such as the toll-like receptors. The activation of macrophages results in functional consequences such as microbicidal activity directed especially towards intracellular pathogens, and aided by the expression of peroxides and superoxide radicals. These processes are defective in CGD as will be discussed further. Other secretory effects of macrophages result in the production of a plethora of mediators that assist in immunity and are shown in Figure 3. Several of these are also essential aspects of the antimicrobial function of the macrophages. The NADPH oxidase system is pivotal to the anti-microbial function of the phagocyte (neutrophil or macrophage) and its components need to be discussed in some detail in order to understand the molecular pathogenesis and classification of CGD. These aspects are shown in Figure 4 and are discussed later.

Mechanisms Involved in CGD

7CGD represents a heterogeneous group of disorders characterized by defective generation of a respiratory burst in human phagocytes (neutrophils, mononuclear cells, macrophages, and eosinophils). The resultant defect is an inability to generate superoxide and hence an inability to contain certain infectious pathogens. The disease manifests as repeated, severe bacterial and fungal infections resulting in the formation of inflammatory granulomas. The earliest report of the disease was in 1954 by Janeway and colleagues. Landing and Shirkey subsequently described a patient with recurrent infection and associated histiocyte infiltration. A few years later, Bridges and Good reported on a fatal granulomatous disorder in boys and described this as a "new syndrome". Since these early descriptions, a rather amazing and accelerated understanding of the disease and its molecular genetics have developed in the last 5 decades. Several research groups reported on defective oxidative burst as a possible mechanism of the disease. In 1966, Holmes and colleagues recognized an abnormality of phagocyte function in the disease, while in 1967 Quie and coworkers demonstrated defective in vitro killing of bacteria by phagocytes obtained from patients with CGD. In that same year, Baehner and Nathan described defective reduction of nitroblue tetrazolium by phagocytes from patients with CGD during phagocytosis, and postulated this as a diagnostic test. This was a seminal paper that led to the critical test used to screen for the disease for decades. This has now been replaced by a flow cytometric assay for the oxidative burst. In 1968, Baehner and Karnovsky demonstrated a deficiency of reduced nicotinamide-adenine dinucleotide oxidase in patients with CGD. This was followed by the demonstration of defective superoxide generation from the phagocytes of patients with CGD by Curnette et al., and confirmation of defective NADPH oxidase expression in the disease by Hohn and Lehrer. In 1986, Baehner reported on the gene localization for X-linked CGD to xp21. Subsequently, defects in several components of the NADPH oxidase complex, including the gp91phox, p22 phox, p67phox, and p47phox were described by various researchers.

8The presumed mechanism of CGD and the associated defects in NADPH oxidase system are shown in Figure 4. The assembly of the various subunits of NADPH oxidase is shown in the figure, while the molecular genetics, rough prevalence, inheritance pattern, and chromosomal localization are shown in the bottom of the figure. There are several components of NADPH oxidase: of these the cytochrome-b558 heterodimer is located in the membrane and consists of the gp91phox and p22phox units, while three cytosolic components exist- including the p67phox, p47phox, and a p40phox. Following cellular activation, the soluble cytosolic components, p67phox, p47phox, and a p40phox, move to the membrane and bind to components of the cytochrome-b558 heterodimer. This is also accompanied by the binding of the GTPase protein, Rac, culminating by unclear mechanisms in flavocytochrome activation. This catalyzes the transfer of electrons from NADPH to oxygen, resulting in the formation of superoxide in the extracellular component as shown in Figure 4. Subsequent reactions via superoxide dismutase (SOD), catalase or myeloperoxidase (MPO), occurring in the phagolysome, can result in formation of H2O2, H2O, or HOCl- respectively. Recent data suggest that the formation of superoxides and reactive oxygen species is not the end-all of these reactions, as such mediators may also set off subsequent activation of granule proteins such as cathepsin G and elastase, leading to further elaboration of the immune-inflammatory response, all of which are therefore likely to be defective in CGD.

Molecular subtypes and Genetics of CGD

9X-linked CGD (XL-CGD) arises due to mutations in the gp91phox gene and is responsible for 65-70% of the clinical cases in the United States. This gene is termed CYBB and spans a 30 kb region in the Xp21.1 region (Figure 4). Deletions, frameshift, missense, nonsense, and splice site mutations have been described in this gene. When larger X-chromosomal deletions including the XK gene occur, this may result in a so-called "Contiguous gene syndrome". This may result in associations of the Kell phenotype/Mcleod syndrome with X-linked chronic granulomatous disease (CGD; OMIM 306400), Duchenne muscular dystrophy (DMD; OMIM 310200), and X-linked retinitis pigmentosa (RP3; OMIM 300389).

10Autosomal recessive CGD (AR-CGD), seen in the remaining 35% cases, arise due to mutations of the other components of the NADH oxidase (except p40phox and Rac which are yet to be associated with any CGD phenotype): these include- p22phox, p67phox and p47phox. Of these, the dominant mutations observed is of the p22phox gene which accounts for almost 25% cases. The chromosomal location, MIM number, inheritance, and frequency are shown in Figure 4. These phenotypes can be referred to as the X-CGD and as the A22/A47/A67 CGD. Of these subtypes, A47 patients appear to have a less severe course. Nevertheless, extreme heterogeneity may be seen in the manifestations of this disease. Perhaps concomitant immune defects such as those of IgA deficiency or mannose binding lectin mutations (MBL) might be responsible for some of the observed heterogeneity in severity and/or disease progression. These aspects need further study.

Clinical Features

11Patients with CGD usually present in infancy or childhood with repeated, severe bacterial and/or fungal infections. However, delayed diagnosis in adulthood is also possible as is occurrence in females. The disease is relatively uncommon, affecting about 1/250,000 individuals. The most common manifestations include infection, granulomatous disease, inflammation, and failure to thrive (nutritional effects of chronic infection and inflammation). The disease is heterogeneous in its manifestations, related to the subtypes, and severity of the associated macrophage defect. In the majority of patients, the production of superoxides is undetetectable and the manifestations are therefore early and predictable to a great extent. In others, low level respiratory burst activity may delay manifestations or diagnosis into early adulthood. Most patients present with infectious illness, which include sinopulmonary disease, abscesses, or lymphadenitis. Other manifestations are related more to inflammatory consequences and/or structural disease and resultant organ dysfunction.

12The following sections will discuss the clinical aspects of CGD (X-linked disease and the autosomal recessive disease counterparts), the Kell-deletion/Mcleod syndrome, association with MBL deficiency and other deficiencies and rare clinical manifestations of the carrier state.

Clinical Aspects

13CGD presents most often with infectious illness, though some patients may present with a failure to thrive, granulomatous complications, or inflammatory disease. The disease is usually diagnosed in childhood and sometimes in early adulthood. Table 5 lists the infectious and Table 6 the inflammatory consequences of CGD. Over 90% of the patients with confirmed CGD have severe respiratory burst defects resulting in little or no expression of superoxide radicals. These patients usually present early in life (usually in infancy) as severe or life threatening bacterial or fungal infections. On the other hand, some patients might present in late childhood or early adulthood with recurrent and unusual infections, leading to the diagnosis. Typical infections include purulent bacterial infections (such as pneumonias, sinusitis or liver abscess) or necrotizing fungal infections of deep tissue or bone. As shown in Table 5, common pathogens include the gram negative Enterobacteriaciae, Staphylococcus, Nocardia, Aspergillus, Candida and atypical Mycobacteria. Other bacterial include- Burkholderia species and Chromobacterium violaceum. Many apparent infections go undetected on cultures and may require special efforts to determine a specific etiological organism. At least in Sweden, patients with X-linked disease had more infections than the AR counterparts, with dermal abscesses more commonly seen than lymphadenitis or pneumonias. In the Japanese experience at one hospital, of 23 patients treated, nearly half had Aspergillus infection of the lungs, while short staure and underweight were a complication in up to 1/5th of the patients. Failure to thrive was also observed in the UK series reported, where the incidence of growth failure was much higher and listed at 75%. Aspergillus as a major cause of morbidity and mortality was also observed in the German cohort, where patients with severe involvement of cytochrome b558 were the most likely to manifest complications at an early age and also suffer from more infections compared to those with AR disease. Liese and coworkers described 11 patients with delayed presentations and diagnosis as late as 22 years of age, of which eight had X-linked disease but residual cytochrome function and three had the AR disease, while nine out of the eleven patients had some residual production of reactive oxygen metabolites, explaining their delayed presentation. In a European cohort study consisting of 429 patients, 67% had X-linked disease and 33% had the AR counterpart. The patient population consisted of 351 males and 78 females. According to retrospective data collected in this series of patients, AR disease was diagnosed later and the mean survival time was significantly better in these patients (49.6 years) than in XL disease (37.8 years), compatible with other reports from the United States and elsewhere. Pulmonary (66% of patients), dermatological (53%), lymphatic (50%), alimentary (48%), and hepatobiliary (32%) complications were the most frequently observed. Staphylococcus aureus, Aspergillus spp, and Salmonella spp. were the most common cultured pathogens in that order, while Pseudomonas spp. and Burkholderia cepacia were rarely observed. Roughly 3/4th of the patients received antibiotic prophylaxis, 1/2 antifungal prophylaxis, and 1/3rd-received gamma-interferon. Less than 10% of the patients had received stem cell transplantation. Bacterial pneumonia and/or pulmonary abscess, systemic sepsis and brain abscess were the leading causes of death in this series. The differences between the European and United States data/observations are shown in Table 7.

14Winkelstein and coworkers reported on the United States CGD experience. Of the 368 patients registered, 259 had the XL-CGD, 81 had AR-CGD, and in the remaining cases the mode of inheritance was unknown. Pneumonia, suppurative adenitis, subcutaneous abscess, liver abscess, osteomyelitis, and sepsis were the most frequently observed complications, in that order (Table 8). Other complications (Table 6) included gastric outlet obstruction, urinary tract obstruction, and granulomatous colitis or enteritis. A small fraction of the XL- and AR-CGD kindreds reported the occurrence of lupus in family members. The most common causes of death were pneumonia and/or sepsis due to Aspergillus or Burkholderia cepacia. As noted earlier and confirmed in the United States experience, patients with XL-CGD had a more severe phenotype than those with the AR form of the disease.

Sinopulmonary Complications

15Pneumonia as stated earlier is often the most common complication of the disease. Infections with catalase-positive organisms are the rule. In many cases, no organism is cultured even though the patients are often treated with and respond to antimicrobials directed against bacteria or fungi. The diagnosis of pulmonary involvement is most often made clinically, complemented by radiology (chest roentgenography, computerized tomography or MRI), biopsy, and cultures. Airway obstruction that sometimes complicates infection/granulomatous disease is best diagnosed by pulmonary function tests and by bronchoscopy. Recurrent pneumonia, lung abscess, effusions and empyema thoracis, mediastinal adenopathy, and necrotizing nodular disease may be seen. The common pathogens include Staphylococcus aureus, Burkholderia cepacia, Serratia marcescens, Nocardia, and Aspergillus spp. In the series reported by Winkelstein et al., pneumonia accounted for 79% of the infectious complications of CGD. Genetically, variant alleles of mannose binding lectin (MBL) were associated with autoimmune disease and may predispose to some pulmonary complications. Chest wall invasion by pathogens has also been described and may be due to necrotizing infections by fungi such as Aspergillus. Pulmonary infections have also been described due to Pneumocystis carinii, Cryptococcus neoformans, Aspergillus, visceral Leishmaniasis, suppurative pathogens, Pseudomonas cepacia,, Legionella, Nocardia, Mycoplasma pneumoniae, Sarcinosporon inkin-a skin fungus, Tuberculosis, Trichosporon pullulans, Tularemia, Q Fever, Acremonium kiliense, Botryomycosis, Chrysosporium zonatum, Burkholderia (Pseudomonas) gladioli, fulminant mulch/filamentous fungi, Respiratory Syncitial Virus, and Francisella philomiragia (formerly Yersinia philomiragia). Certain pneumonic variants have also been described in CGD, including crystalline, nodular, and eosinophilic pneumonias.

Ocular Complications

16Blepharokeratoconjunctivitis, marginal keratitis, and choroido-retinal scars have all been described in CGD. A case of congenital arteriovenous hemangioma, presumably related to defective phagocyte function and hemosiderin removal, was described in a patient with CGD.

Neurological Complications

17Patients with CGD can develop several neurological complications. Brain abscess has been well described in patients with CGD. Various pathogens have been associated with brain abscess development including Scedosporium prolificans, Alternaria infectoria, Salmonella enterica subspecies houtenae, and Aspergillus. Other complications associated with CGD include white matter disease, CNS granulomatous disease and leptomeningeal, and focal brain infiltration by pigmented, lipid-laden macrophages. Several reports of fungal brain infection, Aspergillus abscess resembling a brain tumor, spinal cord infection by Aspergillus and fungal granuloma of the brain have been described. Meningitis due to Streptococcus and Candida has also been reported on.

Hepatobiliary and GI Complications

18A plethora of GI tract complications occur in CGD. As stated earlier, variant alleles of mannose binding lectin (MBL) were associated with autoimmune disease while polymorphisms of myeloperoxidase and Fc γ RIII were associated more with gastrointestinal complications in patients with CGD. As summarized by Barton et al., GI tract disorders can present from the mouth to the anus, and can be characterized by ulcers, abscesses, fistulae, strictures, and obstructive symptoms. Inflammatory granulomatous colitis can also lead to obstructive disease, diarrhea, malabsorption, or other manifestations. Appendicitis, perirectal abscess, salmonella enteritis, and acalculous cholecystitis have been described, some requiring surgical intervention.

19Gastric outlet obstruction is a recognized complication. A case of gastric outlet obstruction due to diffuse gastric infiltration has also been described. There have been reports of nonsurgical resolution of gastric outlet obstruction following the use of glucocorticoids and antibiotics. Liver involvement in the form of hepatic granuloma or multiple hepatic abscesses can complicate management.

20Hepatic involvement by Staphylococcus aureus and Pseudomonas cepacia can manifest as granuloma or abscess formation. A rare case of ascites has been described in CGD and non-cirrhotic portal hypertension was reported to have prognostic significance. In one study of 194 patients from the NIH, elevated liver enzymes (mainly transaminitis) were documented in >75%, liver abscess in 35%, hepatomegaly in 34%, and splenomegaly in over 50% cases. Liver histology demonstrated granuloma in 75% and lobular hepatitis in 90%. Venopathy of the portal vein was observed in 80% and was associated with splenomegaly. Ament and Ochs commented on the occurrence of several gastrointestinal manifestations in patients with CGD- including granulomata on biopsy, malabsorption syndromes, and B12-deficiency. Interferon gamma therapy, careful use of glucocorticoids and liver transplantation have improved outcomes in some patients with liver involvement. Chronic infection, nausea, vomiting, and malabsorption can lead to weight loss and/or failure to thrive in patients with CGD. Catch up growth tends to occur and many patients attain predicted heights by late adolescence.

Renal and Gentourinary Complications

21Granulomatous involvement and/or infectious complications can result in major genitourinary complications in patients with CGD. Use of glucocorticoids and antimicrobials has resulted in remission of obstructive pathology in some patients, thereby avoiding surgery. Frifeit and coworkers described chronic glomerulonephritis in a 12 year old male with CGD. This culminated in terminal uremia and fatal pulmonary Aspergillosis and Pseudomonas septicemia. Diffuse infiltration of renal and other tissues by pigment-containing macrophages may also result in pathology in CGD. Renal Aspergilloses resulting in renal abscess formation has also been described as well as xantogranulomatous pyelonephritis and renal amyloidosis. In the latter case, renal amyloidosis resulting in nephritic syndrome occurred in a patient with CGD post-renal transplantation. In one series, 23/60 patients (38%) with CGD demonstrated urological disease, including bladder granulomas, urethral strictures, recurrent urinary tract infections, and renal dysfunction. The judicious use of glucocorticoids and interferon gamma has had a beneficial effect on several of these conditions of either the genitourinary or gastrointestinal systems.

Other Complications

22Dermatological manifestations in patients with CGD include atopic dermatitis-like disease but with systemic or deep seated infections, facial granulomata and discoid lupus, and seborrheic dermatitis-like disease. Vesicular and granulomatous of fungal skin lesions have been observed in small reports. Altered skin Rebuck window responses in patients with CGD have been recorded. Several skeletal complications related mainly to infections have been described in patients with CGD. Osteomyelitis secondary to invasive Aspergillus or Burkholderia gladioli may occur. Osteomyelitis may involve either the long bones or even the spine. Dactylitis may complicate CGD. Multifocal osteomyelitis secondary to Paecilomyces varioti has also been reported as has sacral osteomyelitis secondary to Basidiomycetous fungi such as Inonotus tropicalis. Gill et al., reported on a favorable response to Interferon gamma in osteomyelitis complicating CGD. Occasionally recombinant hematopoietic growth factors (rhG-CSF), long term antimicrobials, and surgery may be required in the management of these complex patients.

Inflammatory Responses in CGD

23Table 6 lists the inflammatory and structural changes observed in CGD. Some of these changes may truly represent infectious complications, but as stated earlier, many such tissues fail to grow any identifiable pathogens in culture. These changes may also represent the exuberant inflammatory response seen in the disease. Whether these changes represent an overwhelming response to infection by other intact components of the immune response (such as T cells and B cells) and manifested by hyperglobulinemia and elevated acute phase reactants, a failure of the compensatory "anti-inflammatory response", a diminished production of specific regulatory products such as PGE2 or activation of nuclear factor kappaB, the ubiquitous transcription fact is unclear. This in addition to the poor superoxide radical response, failure of phagocytosis and the enhanced cytokine responses may be responsible for the observed inflammatory pathologies listed in Table 6. At least in a murine model, the failure of an immune-modulatory effect of superoxide radicals was associated with exuberant inflammatory responses and TH17-mediated pathology and arthritis. The development of animal models of CGD to study this "hyperinflammation" further will improve our understanding of the immune dysregulation seen in the disease. Granuloma formation is often accompanied by inflammatory, obstructive, or functional impairments of organ systems, such as the GI tract or the GU system.

Other Aspects of CGD

24In some patients with CGD, the deletion in the Xp21 can extend to other "contiguous" genes resulting in an association of the disease with lack of Kell blood antigens (Mcleod phenotype), Retinitis Pigmentosa, and Duchenne Muscular Dystrophy. This could complicate blood transfusion. There have been reports of successful granulocyte transfusions in patients with the Mcleod Phenotype, complicated only by mild hemolysis.

25Female carriers have manifested some symptoms, such as dermatitis, stomatitis, and discoid lupus-like disease. CGD-like infections can sometimes present in female carriers, and these patients demonstrate both normal and CGD-neutrophils with functional mosaicism. In one report of 15 carriers of the CGD gene, five patients had both stomatitis and discoid SLE-like lesions and five patients had stomatitis alone, while the remaining five patients were relatively asymptomatic. Martin-Villa and co-workers also described more frequent autoantibodies among carriers of the CGD gene compared to non-carrier relatives, probably related to random X-chromosome inactivation.

26Concomitant immune deficiencies may complicate CGD and contribute to infectious complications. In patients with documented CGD, variant alleles of mannose binding lectin (MBL) were associated with autoimmune disease and may predispose to some pulmonary complications. There have been several reports of IgA deficiency in patients with CGD. Further studies of humoral immune response and MBL deficiency in patients with CGD are essential to further understand these immune interactions and predisposition to autoimmunity and infectious disease.

Diagnosis and Treatment

27The approach to the diagnosis of CGD is shown in Table 9. Many of the clinical and laboratory abnormalities suggest the diagnosis. The confirmatory test is measurement of the oxidative burst (superoxide production) of the neutrophil in response to stimulation. While the NBT slide test was commonly used in the past, this has been replaced recently by the dihydrorhodamine 123 (DHR) and flow cytometric analysis- the DHR test. The DHR test has the ability to distinguish X-linked from the AR forms of the disease as well as pick up the carrier state. Other tests proposed include denaturing high-performance liquid chromatography (DHPLC) system and real time PCR-based assays. Molecular mutational analysis can help confirm the diagnosis, define the defect, and classify the patient into specific subtypes.

28Treatment of CGD includes prophylaxis of infections using interferon gamma and appropriate antimicrobials (such as trimethoprim sulfamethoxazole/TMP-SMX and itraconazole), and management of infections using appropriate antimicrobials based on pathogen likelihood or identification. In select situations, granulocyte transfusions may be required. The roles for stem cell transplant (HLA identical sibling umbilical cord stem cell transplantation (UCSCT) after myeloablative conditioning) and gene therapy need to be defined. Allogeneic hematopoietic stem cell transplantation from a HLA-identical donor may, at present, be the only proven curative treatment for CGD. Summaries of various treatment options are provided in Table 10.

Competing interests

29The authors declare that they have no competing interests.

Authors' contributions

30ES- organized manuscript, assisted in writing treatment portion; GJ- organized manuscript, assisted in writing treatment portion; HS- assisted with manuscript review and corrections; WJ- assisted with manuscript review, references and corrections; RS- assisted with manuscript editing, assignment of figures and tables and generation of some of the tables; GK- conceived of the manuscript, generated all figures and developed the format. All authors have read and approved the final manuscript.

References 192

1.
Janeway CA Hypergammaglobulinemia associated with severe, recurrent and chronic non-specific infectionAm J Dis Child1954 88388392
Not in our library
2.
Landing BH Shirkey HS A syndrome of recurrent infection and infiltration of viscera by pigmented lipid histiocytesPediatrics1957 20431438
Not in our library
3.
Bridges RA Berendes H Good RA A fatal granulomatous disease of childhood; the clinical, pathological, and laboratory features of a new syndromeAMA J Dis Child1959 97387408
Not in our library
4.
Seger RA Advances in the diagnosis and treatment of chronic granulomatous diseaseCurr Opin Hematol2010
Not in our library10.1097/moh.0b013e32834115e7
5.
EditorialMicrobial killing by neutrophilsLancet1976 113931394
Not in our library
6.
Phagocytic defects IIAbnormalities of the respiratory burstHematol Oncol Clin North Am1988 2185336
Not in our library
7.
Babior BM The respiratory burst oxidaseHematol Oncol Clin North Am1988 2201212
Not in our library
8.
Borregaard N Activation of phagocytesEur J Clin Invest1985 15240241
Not in our library10.1111/j.1365-2362.1985.tb00176.x
9.
Holmes B Fatal granulomatous disease of childhood. An inborn abnormality of phagocytic functionLancet1966 112251228
Not in our library10.1016/s0140-6736(66)90238-8
10.
Quie PG In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhoodJ Clin Invest1967 46668679
Not in our library10.1172/jci105568
11.
Baehner RL Nathan DG Leukocyte oxidase: defective activity in chronic granulomatous diseaseScience1967 155835836
Not in our library10.1126/science.155.3764.835
12.
Baehner RL Nathan DG Quantitative nitroblue tetrazolium test in chronic granulomatous diseaseN Engl J Med1968 278971976
Not in our library10.1056/nejm196805022781801
13.
Baehner RL Karnovsky ML Deficiency of reduced nicotinamide-adenine dinucleotide oxidase in chronic granulomatous diseaseScience1968 16212771279
Not in our library10.1126/science.162.3859.1277
14.
Curnutte JT Whitten DM Babior BM Defective superoxide production by granulocytes from patients with chronic granulomatous diseaseN Engl J Med1974 290593597
Not in our library10.1056/nejm197403142901104
15.
Hohn DC Lehrer RI NADPH oxidase deficiency in X-linked chronic granulomatous diseaseJ Clin Invest1975 55707713
Not in our library10.1172/jci107980
16.
Segal AW Absence of both cytochrome b-245 subunits from neutrophils in X-linked chronic granulomatous diseaseNature1987 3268891
Not in our library10.1038/326088a0
17.
Baehner RL Chronic granulomatous disease of childhood: clinical, pathological, biochemical, molecular, and genetic aspects of the diseasePediatr Pathol1990 10143153
Not in our library10.3109/15513819009067103
18.
Umei T Takeshige K Minakami S NADPH-binding component of the superoxide-generating oxidase in unstimulated neutrophils and the neutrophils from the patients with chronic granulomatous diseaseBiochem J1987 243467472
Not in our library10.1042/bj2430467
19.
Curnutte JT Kuver R Scott PJ Activation of neutrophil NADPH oxidase in a cell-free system. Partial purification of components and characterization of the activation processJ Biol Chem1987 26255635569
Not in our library
20.
Bjorgvinsdottir H Zhen L Dinauer MC Cloning of murine gp91phox cDNA and functional expression in a human X-linked chronic granulomatous disease cell lineBlood1996 8720052010
Not in our library
21.
Casimir C Identification of the defective NADPH-oxidase component in chronic granulomatous disease: a study of 57 European familiesEur J Clin Invest1992 22403406
Not in our library10.1111/j.1365-2362.1992.tb01481.x
22.
Curnutte JT Chronic granulomatous disease: the solving of a clinical riddle at the molecular levelClin Immunol Immunopathol1993 67S215
Not in our library10.1006/clin.1993.1078
23.
Roos D The genetic basis of chronic granulomatous diseaseImmunol Rev1994 138121157
Not in our library10.1111/j.1600-065x.1994.tb00850.x
24.
Kinnon C Levinsky R The molecular basis of X-linked immunodeficiency diseaseJ Inherit Metab Dis1992 15674682
Not in our library10.1007/bf01799623
25.
Bertelson CJ Localization of the McLeod locus (XK) within Xp21 by deletion analysisAm J Hum Genet1988 42703711
Not in our library
26.
Brown J Analysis of three deletion breakpoints in Xp21.1 and the further localization of RP3Genomics1996 37200210
Not in our library10.1006/geno.1996.0543
27.
Al-Khuwaitir TS Chronic granulomatous disease with recurrent hepatic abscesses in an adultSaudi Med J2007 2815931596
Not in our library
28.
Aliabadi H Gonzalez R Quie PG Urinary tract disorders in patients with chronic granulomatous diseaseN Engl J Med1989 321706708
Not in our library10.1056/nejm198909143211102
29.
Becker CE Graddick SL Roy TM Patterns of chronic granulomatous diseaseJ Ky Med Assoc1993 91447450
Not in our library
30.
Winkelstein JA Chronic granulomatous disease. Report on a national registry of 368 patientsMedicine (Baltimore)2000 79155169
Not in our library10.1097/00005792-200005000-00003
31.
Antachopoulos C Walsh TJ Roilides E Fungal infections in primary immunodeficienciesEur J Pediatr2007 16610991117
Not in our library10.1007/s00431-007-0527-7
32.
Alsultan A Chronic granulomatous disease presenting with disseminated intracranial aspergillosisPediatr Blood Cancer2006 47107110
Not in our library10.1002/pbc.20426
33.
Ahlin A Prevalence, genetics and clinical presentation of chronic granulomatous disease in SwedenActa Paediatr1995 8413861394
Not in our library10.1111/j.1651-2227.1995.tb13575.x
34.
Kobayashi S Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in JapanEur J Pediatr2008 16713891394
Not in our library10.1007/s00431-008-0680-7
35.
Jones LB Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registryClin Exp Immunol2008 152211218
Not in our library10.1111/j.1365-2249.2008.03644.x
36.
Liese J Long-term follow-up and outcome of 39 patients with chronic granulomatous diseaseJ Pediatr2000 137687693
Not in our library10.1067/mpd.2000.109112
37.
Liese JG Chronic granulomatous disease in adultsLancet1996 347220223
Not in our library10.1016/s0140-6736(96)90403-1
38.
Chronic Granulomatous Disease: The European Experience · 2009
No notice
39.
Foster CB Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous diseaseJ Clin Invest1998 10221462155
Not in our library10.1172/jci5084
40.
Kawashima A Pulmonary Aspergillus chest wall involvement in chronic granulomatous disease: CT and MRI findingsSkeletal Radiol1991 20487493
Not in our library10.1007/bf00194242
41.
Altman AR Thoracic wall invasion secondary to pulmonary aspergillosis: a complication of chronic granulomatous disease of childhoodAJR Am J Roentgenol1977 129140142
Not in our library10.2214/ajr.129.1.140
42.
Adinoff AD Chronic granulomatous disease and Pneumocystis carinii pneumoniaPediatrics1982 69133134
Not in our library
43.
Markus MR Chronic granulomatous disease and Pneumocystis carinii pneumoniaS Afr Med J1983 63350
Not in our library
44.
Pedersen FK Refractory Pneumocystis carinii infection in chronic granulomatous disease: successful treatment with granulocytesPediatrics1979 64935938
Not in our library
45.
Allen DM Chng HH Disseminated Mycobacterium flavescens in a probable case of chronic granulomatous diseaseJ Infect1993 268386
Not in our library10.1016/0163-4453(93)97000-n
46.
Chudwin DS Aspergillus pneumonia in chronic granulomatous disease: recurrence and long-term outcomeActa Paediatr Scand1982 71915917
Not in our library10.1111/j.1651-2227.1982.tb09548.x
47.
Chusid MJ Sty JR Wells RG Pulmonary aspergillosis appearing as chronic nodular disease in chronic granulomatous diseasePediatr Radiol1988 18232234
Not in our library10.1007/bf02390402
48.
Conrad DJ Microgranulomatous aspergillosis after shoveling wood chips: report of a fatal outcome in a patient with chronic granulomatous diseaseAm J Ind Med1992 22411418
Not in our library10.1002/ajim.4700220313
49.
Kelly JK Fatal Aspergillus pneumonia in chronic granulomatous diseaseAm J Clin Pathol1986 86235240
Not in our library10.1093/ajcp/86.2.235
50.
Kosut JS Kamani NR Jantausch BA One-month-old infant with multilobar round pneumoniasPediatr Infect Dis J2006 259597
Not in our library10.1097/01.inf.0000195717.40250.8b
51.
Asensi V Visceral leishmaniasis and other severe infections in an adult patient with p47-phox-deficient chronic granulomatous diseaseInfection2000 28171174
Not in our library10.1007/s150100050074
52.
Carnide EG Clinical and laboratory aspects of chronic granulomatous disease in description of eighteen patientsPediatr Allergy Immunol2005 1659
Not in our library10.1111/j.1399-3038.2005.00225.x
53.
Clegg HW Ephros M Newburger PE Pseudomonas cepacia pneumonia in chronic granulomatous diseasePediatr Infect Dis1986 5111
Not in our library
54.
O'Neil KM Pseudomonas cepacia: an emerging pathogen in chronic granulomatous diseaseJ Pediatr1986 108940942
Not in our library10.1016/s0022-3476(86)80934-9
55.
Sieber OF Jr Fulginiti VA Pseudomonas cepacia pneumonia in a child with chronic granulomatous disease and selective IgA deficiencyActa Paediatr Scand1976 65519520
Not in our library10.1111/j.1651-2227.1976.tb04924.x
56.
Ephros M Legionella gormanii pneumonia in a child with chronic granulomatous diseasePediatr Infect Dis J1989 8726727
Not in our library10.1097/00006454-198910000-00014
57.
Peerless AG Legionella pneumonia in chronic granulomatous diseaseJ Pediatr1985 106783785
Not in our library10.1016/s0022-3476(85)80355-3
58.
McNeil MM Disseminated Nocardia transvalensis infection: an unusual opportunistic pathogen in severely immunocompromised patientsJ Infect Dis1992 165175178
Not in our library10.1093/infdis/165.1.175
59.
Johnston HC Nocardia pneumonia in a neonate with chronic granulomatous diseasePediatr Infect Dis J1989 8526528
Not in our library10.1097/00006454-198908000-00011
60.
Jonsson S Recurrent Nocardia pneumonia in an adult with chronic granulomatous diseaseAm Rev Respir Dis1986 133932934
Not in our library
61.
Shetty AK Arvin AM Gutierrez KM Nocardia farcinica pneumonia in chronic granulomatous diseasePediatrics1999 104961964
Not in our library10.1542/peds.104.4.961
62.
Kato M [Mycoplasma pneumoniae pneumonia in patients with chronic granulomatous disease]Kansenshogaku Zasshi1983 57823827
Not in our library10.11150/kansenshogakuzasshi1970.57.823
63.
Kenney RT Invasive infection with Sarcinosporon inkin in a patient with chronic granulomatous diseaseAm J Clin Pathol1990 94344350
Not in our library10.1093/ajcp/94.3.344
64.
Lee PP Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosisPediatr Infect Dis J2008 27224230
Not in our library10.1097/inf.0b013e31815b494c
65.
Lestini BJ Church JA Trichosporon pullulans as a complication of chronic granulomatous disease in a patient undergoing immunosuppressive therapy for inflammatory bowel diseasePediatr Infect Dis J2006 258789
Not in our library10.1097/01.inf.0000195641.69380.a0
66.
Moylett EH Chinen J Shearer WT Trichosporon pullulans infection in 2 patients with chronic granulomatous disease: an emerging pathogen and review of the literatureJ Allergy Clin Immunol2003 11113701374
Not in our library10.1067/mai.2003.1522
67.
Maranan MC Pneumonic tularemia in a patient with chronic granulomatous diseaseClin Infect Dis1997 25630633
Not in our library10.1086/513777
68.
Meis JF Rapidly fatal Q-fever pneumonia in a patient with chronic granulomatous diseaseInfection1992 20287289
Not in our library10.1007/bf01710798
69.
Acremonium kiliense infection in a child with chronic granulomatous disease
Not checked
70.
Paz HL Primary pulmonary botryomycosis. A manifestation of chronic granulomatous diseaseChest1992 10111601162
Not in our library10.1378/chest.101.4.1160
71.
Roilides E Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus fungal infections in patients with this diseaseJ Clin Microbiol1999 371825
Not in our library10.1128/jcm.37.1.18-25.1999
72.
Ross JP Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: report of two successfully treated casesClin Infect Dis1995 2112911293
Not in our library10.1093/clinids/21.5.1291
73.
Siddiqui S Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous diseaseClin Infect Dis2007 45673681
Not in our library10.1086/520985
74.
Uzel G Respiratory syncytial virus infection in patients with phagocyte defectsPediatrics2000 106835837
Not in our library10.1542/peds.106.4.835
75.
Wenger JD Infection caused by Francisella philomiragia (formerly Yersinia philomiragia). A newly recognized human pathogenAnn Intern Med1989 110888892
Not in our library10.7326/0003-4819-110-11-888
76.
Trawick D Eosinophilic pneumonia as a presentation of occult chronic granulomatous diseaseEur Respir J1997 1021662170
Not in our library10.1183/09031936.97.10092166
77.
Narchi H Gammoh S Multiple nodular pneumonitis in a three-week-old female infantPediatr Infect Dis J1999 18471486
Not in our library10.1097/00006454-199905000-00016
78.
Palestine AG Ocular findings in patients with neutrophil dysfunctionAm J Ophthalmol1983 95598604
Not in our library10.1016/0002-9394(83)90377-x
79.
Djalilian AR Keratitis caused by Candida glabrata in a patient with chronic granulomatous diseaseAm J Ophthalmol2001 132782783
Not in our library10.1016/s0002-9394(01)01091-1
80.
Andersen SR Vascular lesion (arteriovenous aneurysm or haemangioma) of the orbit in a case of chronic granulomatous diseaseOphthalmologica1976 173145151
Not in our library10.1159/000307875
81.
Bhat SV Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafineScand J Infect Dis2007 398790
Not in our library10.1080/00365540600786564
82.
Hipolito E Alternaria infectoria brain abscess in a child with chronic granulomatous diseaseEur J Clin Microbiol Infect Dis2009 28377380
Not in our library10.1007/s10096-008-0623-2
83.
Ma JS Brain abscess caused by Salmonella enterica subspecies houtenae in a patient with chronic granulomatous diseaseJ Microbiol Immunol Infect2003 36282284
Not in our library
84.
Narita M A case of chronic granulomatous disease in which the patient survived a recurrence of suspected Aspergillus brain abscessKansenshogaku Zasshi1999 73783786
Not in our library10.11150/kansenshogakuzasshi1970.73.783
85.
Saulsbury FT Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous diseaseClin Infect Dis2001 32E137E139
Not in our library10.1086/320158
86.
Hadfield MG Brain lesions in chronic granulomatous diseaseActa Neuropathol1991 81467470
Not in our library10.1007/bf00293469
87.
Walker DH Okiye G Chronic granulomatous disease involving the central nervous systemPediatr Pathol1983 1159167
Not in our library10.3109/15513818309040653
88.
Riggs JE Pigmented, lipid-laden histiocytes in the central nervous system in chronic granulomatous disease of childhoodJ Child Neurol1989 46163
Not in our library10.1177/088307388900400111
89.
Leto TL Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-srcScience1990 248727730
Not in our library10.1126/science.1692159
90.
Patiroglu T Atypical presentation of chronic granulomatous disease in an adolescent boy with frontal lobe located Aspergillus abscess mimicking intracranial tumorChilds Nerv Syst2010 26149154
Not in our library10.1007/s00381-009-1003-7
91.
Bukhari E Alrabiaah A First case of extensive spinal cord infection with Aspergillus nidulans in a child with chronic granulomatous diseaseJ Infect Dev Ctries2009 3321323
Not in our library10.3855/jidc.132
92.
Turgut M Fungal granuloma of the brain caused by Aspergillus in an adolescent boy with chronic granulomatous diseaseChilds Nerv Syst2010 26733734
Not in our library10.1007/s00381-010-1149-3
93.
Garel D [Streptococcus group B tardive meningitis revealing chronic septic granulomatosis]Ann Pediatr (Paris)1989 363537
Not in our library
94.
Fleischmann J Church JA Lehrer RI Primary Candida meningitis and chronic granulomatous diseaseAm J Med Sci1986 291334341
Not in our library10.1097/00000441-198605000-00009
95.
Barton LL Gastrointestinal complications of chronic granulomatous disease: case report and literature reviewClin Pediatr (Phila)1998 37231236
Not in our library10.1177/000992289803700403
96.
Mulholland MW Delaney JP Simmons RL Gastrointestinal complications of chronic granulomatous disease: surgical implicationsSurgery1983 94569575
Not in our library
97.
Huang A Abbasakoor F Vaizey CJ Gastrointestinal manifestations of chronic granulomatous diseaseColorectal Dis2006 8637644
Not in our library10.1111/j.1463-1318.2006.01030.x
98.
Saul RA Gastric outlet obstruction in chronic granulomatous diseaseJ Pediatr1989 114505
Not in our library10.1016/s0022-3476(89)80584-0
99.
Born M Willinek WA Hassan C [Gastric outlet obstruction in chronic granulomatous disease]Z Gastroenterol2002 40511516
Not in our library10.1055/s-2002-32799
100.
Dickerman JD Colletti RB Tampas JP Gastric outlet obstruction in chronic granulomatous disease of childhoodAm J Dis Child1986 140567570
Not in our library10.1001/archpedi.1986.02140200077032
101.
Johnson FE Gastric outlet obstruction due to X-linked chronic granulomatous diseaseSurgery1975 78217223
Not in our library
102.
Varma VA Chronic granulomatous disease of childhood presenting as gastric outlet obstructionAm J Surg Pathol1982 6673676
Not in our library10.1097/00000478-198210000-00009
103.
Hartenberg MA Kodroff MB Chronic granulomatous disease of childhood. Probable diffuse gastric involvementPediatr Radiol1984 145758
Not in our library10.1007/bf02386736
104.
Danziger RN Outpatient management with oral corticosteroid therapy for obstructive conditions in chronic granulomatous diseaseJ Pediatr1993 122303305
Not in our library10.1016/s0022-3476(06)80138-1
105.
Caksen H Recurrent multiple hepatic abscesses, hepatic calcification and congenital hearing loss in a child with chronic granulomatous diseaseActa Paediatr Taiwan2004 45249252
Not in our library
106.
Berlin CM Jr Hepatic granulomata. Presenting with prolonged fever. Resolution with anti-inflammatory treatmentClin Pediatr (Phila)1990 29339342
Not in our library10.1177/000992289002900610
107.
Chen LE Cut it out: Managing hepatic abscesses in patients with chronic granulomatous diseaseJ Pediatr Surg2003 38709713
Not in our library10.1016/jpsu.2003.50189
108.
Fehon R Two-year-old boy with cervical and liver abscessesJ Paediatr Child Health2008 44670672
Not in our library10.1111/j.1440-1754.2008.01398.x
109.
Garel LA Liver involvement in chronic granulomatous disease: the role of ultrasound in diagnosis and treatmentRadiology1984 153117121
Not in our library10.1148/radiology.153.1.6473772
110.
Grund KE Klotter HJ Lemmel EM Chronic granulomatosis as a rare cause of recurrent liver abscessMed Welt1982 33202203
Not in our library
111.
Larsen LR Raffensperger J Liver abscessJ Pediatr Surg1979 14329331
Not in our library10.1016/s0022-3468(79)80493-5
112.
Marchetti F A 7-month-old boy with liver abscessesJ Pediatr Gastroenterol Nutr2010 50117
Not in our library10.1097/mpg.0b013e3181c615b1
113.
Nakhleh RE Glock M Snover DC Hepatic pathology of chronic granulomatous disease of childhoodArch Pathol Lab Med1992 1167175
Not in our library
114.
Castro M Ascites as an unusual manifestation of chronic granulomatous disease in childhoodPediatr Med Chir1992 14317319
Not in our library
115.
Feld JJ Hepatic involvement and portal hypertension predict mortality in chronic granulomatous diseaseGastroenterology2008 13419171926
Not in our library10.1053/j.gastro.2008.02.081
116.
Hussain N Hepatic abnormalities in patients with chronic granulomatous diseaseHepatology2007 45675683
Not in our library10.1002/hep.21524
117.
Ament ME Ochs HD Davis SD Structure and function of the gastrointestinal tract in primary immunodeficiency syndromes. A study of 39 patientsMedicine (Baltimore)1973 52227248
Not in our library10.1097/00005792-197305000-00004
118.
Ament ME Ochs HD Gastrointestinal manifestations of chronic granulomatous diseaseN Engl J Med1973 288382387
Not in our library10.1056/nejm197302222880802
119.
Hadzic N Successful orthotopic liver transplantation for fulminant liver failure in a child with autosomal recessive chronic granulomatous diseaseTransplantation1995 6011851186
Not in our library10.1097/00007890-199511270-00023
120.
Hague RA Resolution of hepatic abscess after interferon gamma in chronic granulomatous diseaseArch Dis Child1993 69443445
Not in our library10.1136/adc.69.4.443
121.
Chin TW Corticosteroids in treatment of obstructive lesions of chronic granulomatous diseaseJ Pediatr1987 111349352
Not in our library10.1016/s0022-3476(87)80452-3
122.
Metin A Gastric antral stricture in a patient with chronic granulomatous diseaseTurk J Pediatr1999 41369373
Not in our library
123.
Safe AF Relapsing Salmonella enteritidis infection in a young adult male with chronic granulomatous diseasePostgrad Med J1991 67198201
Not in our library10.1136/pgmj.67.784.198
124.
Buescher ES Gallin JI Stature and weight in chronic granulomatous diseaseJ Pediatr1984 104911913
Not in our library10.1016/s0022-3476(84)80497-7
125.
Frifelt JJ Chronic granulomatous disease associated with chronic glomerulonephritisActa Paediatr Scand1985 74152157
Not in our library10.1111/j.1651-2227.1985.tb10940.x
126.
Grossniklaus HE Frank KE Jacobs G Chorioretinal lesions in chronic granulomatous disease of childhood. Clinicopathologic correlationsRetina1988 8270274
Not in our library10.1097/00006982-198808040-00009
127.
Myerson DA Rosenfield AT Renal aspergillosis: a report of two casesJ Can Assoc Radiol1977 28214216
Not in our library
128.
Johansen KS Chronic granulomatous disease presenting as xanthogranulomatous pyelonephritis in late childhoodJ Pediatr1982 10098100
Not in our library10.1016/s0022-3476(82)80246-1
129.
Peces R Ablanedo P Seco M [Amyloidosis associated with chronic granulomatous disease in a patient with a renal transplant and recurrent urinary tract infections]Nefrologia2002 22486491
Not in our library
130.
Walther MM The urological manifestations of chronic granulomatous diseaseJ Urol1992 14713141318
Not in our library10.1016/s0022-5347(17)37552-3
131.
Jung K Severe infectious complications in a girl suffering from atopic dermatitis were found to be due to chronic granulomatous diseaseActa Derm Venereol1993 73433436
Not in our library10.2340/0001555573433436
132.
Ahmed I Clinicopathologic challenge. Childhood granulomatous peri-orificial dermatitis with extra-facial lesionsInt J Dermatol2007 46143145
Not in our library10.1111/j.1365-4632.2007.03089.x
133.
Luis-Montoya P Saez-de Ocariz MM Vega-Memije ME Chronic granulomatous disease: two members of a single family with different dermatologic manifestationsSkinmed2005 4320322
Not in our library10.1111/j.1540-9740.2005.03927.x
134.
Dohil M Cutaneous manifestations of chronic granulomatous disease. A report of four cases and review of the literatureJ Am Acad Dermatol1997 36899907
Not in our library10.1016/s0190-9622(97)80269-1
135.
Gallin JI Buescher ES Abnormal regulation of inflammatory skin responses in male patients with chronic granulomatous diseaseInflammation1983 7227232
Not in our library10.1007/bf00917259
136.
Boyanton BL Jr Burkholderia gladioli osteomyelitis in association with chronic granulomatous disease: case report and reviewPediatr Infect Dis J2005 24837839
Not in our library10.1097/01.inf.0000177285.44374.dc
137.
Al-Tawfiq JA Al-Abdely HM Vertebral osteomyelitis due to Aspergillus fumigatus in a patient with chronic granulomatous disease successfully treated with antifungal agents and interferon-gammaMed Mycol2010 48537541
Not in our library10.3109/13693780903325290
138.
Dotis J Roilides E Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatusInt J Infect Dis2004 8103110
Not in our library10.1016/j.ijid.2003.06.001
139.
Dotis J Femoral osteomyelitis due to Aspergillus nidulans in a patient with chronic granulomatous diseaseInfection2003 31121124
Not in our library10.1007/s15010-002-2167-1
140.
Hodiamont CJ Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgeryMed Mycol2009 47217220
Not in our library10.1080/13693780802545600
141.
Kozlowski K Dactylitis secondary to chronic granulomatous disease (report of a case)Radiol Diagn (Berl)1976 17347350
Not in our library
142.
Cohen-Abbo A Edwards KM Multifocal osteomyelitis caused by Paecilomyces varioti in a patient with chronic granulomatous diseaseInfection1995 235557
Not in our library10.1007/bf01710060
143.
Davis CM Basidiomycetous fungal Inonotus tropicalis sacral osteomyelitis in X-linked chronic granulomatous diseasePediatr Infect Dis J2007 26655656
Not in our library10.1097/inf.0b013e3180616cd0
144.
Gill PJ Chronic granulomatous disease presenting with osteomyelitis: favorable response to treatment with interferon-gammaJ Pediatr Orthop1992 12398400
Not in our library10.1097/01241398-199205000-00022
145.
Isotani H Treatment with rhG-CSF for osteomyelitis in a patient with p47-phox-deficient chronic granulomatous diseaseAnn Hematol1997 75243246
Not in our library10.1007/s002770050351
146.
Brown JR Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD)J Leukoc Biol2003 73591599
Not in our library10.1189/jlb.1202599
147.
Bonta IL Adolfs MJ Parnham MJ Distribution and further studies on the activity of prostaglandin E in chronic granulomatous inflammationAgents Actions Suppl1979 121132
Not in our library10.1007/978-3-0348-7232-4_14
148.
Bylund J Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa BEur J Immunol2007 3710871096
Not in our library10.1002/eji.200636651
149.
Carp H Janoff A Potential mediator of inflammation. Phagocyte-derived oxidants suppress the elastase-inhibitory capacity of alpha 1-proteinase inhibitor in vitroJ Clin Invest1980 66987995
Not in our library10.1172/jci109968
150.
Hampton MB Oxidant-mediated phosphatidylserine exposure and macrophage uptake of activated neutrophils: possible impairment in chronic granulomatous diseaseJ Leukoc Biol2002 71775781
Not in our library
151.
Govan JR The Burkholderia cepacia complex and cytokine induction: an inflammatory talePediatr Res2003 54294296
Not in our library10.1203/01.pdr.0000076660.83194.ec
152.
George-Chandy A Th17 development and autoimmune arthritis in the absence of reactive oxygen speciesEur J Immunol2008 3811181126
Not in our library10.1002/eji.200737348
153.
Petersen JE Enhanced cutaneous inflammatory reactions to Aspergillus fumigatus in a murine model of chronic granulomatous diseaseJ Invest Dermatol2002 424429
Not in our library10.1046/j.0022-202x.2001.01691.x
154.
Schappi M Branched fungal beta-glucan causes hyperinflammation and necrosis in phagocyte NADPH oxidase-deficient miceJ Pathol2008 214434444
Not in our library10.1002/path.2298
155.
Casale AJ Bilateral complete ureteral obstruction and renal insufficiency secondary to granulomatous diseaseJ Urol1989 142812814
Not in our library10.1016/s0022-5347(17)38899-7
156.
Francke U Minor Xp21 chromosome deletion in a male associated with expression of Duchenne muscular dystrophy, chronic granulomatous disease, retinitis pigmentosa, and McLeod syndromeAm J Hum Genet1985 37250267
Not in our library
157.
Frey D Gene deletion in a patient with chronic granulomatous disease and McLeod syndrome: fine mapping of the Xk gene locusBlood1988 71252255
Not in our library
158.
Marsh WL Uretsky SC Douglas SD Antigens of the Kell blood group system on neutrophils and monocytes: their relation to chronic granulomatous diseaseJ Pediatr1975 8711171120
Not in our library10.1016/s0022-3476(75)80124-7
159.
Ito K Kell phenotypes in 15 Japanese patients with chronic granulomatous diseaseVox Sang1979 373940
Not in our library10.1111/j.1423-0410.1979.tb02266.x
160.
Brzica SM Jr Chronic granulomatous disease and the Mcleod phenotype. Successful treatment of infection with granulocyte transfusions resulting in subsequent hemolytic transfusion reactionMayo Clin Proc1977 52153156
Not in our library
161.
Brandrup F Discoid lupus erythematosus-like lesions and stomatitis in female carriers of X-linked chronic granulomatous diseaseBr J Dermatol1981 104495505
Not in our library10.1111/j.1365-2133.1981.tb08163.x
162.
Garioch JJ Dermatoses in five related female carriers of X-linked chronic granulomatous diseaseBr J Dermatol1989 121391396
Not in our library10.1111/j.1365-2133.1989.tb01434.x
163.
Humbert JR Frequency of the carrier state for X-linked chronic granulomatous disease among females with lupus erythematosusClin Genet1976 101620
Not in our library10.1111/j.1399-0004.1976.tb00003.x
164.
Rupec RA Lupus erythematosus tumidus and chronic discoid lupus erythematosus in carriers of X-linked chronic granulomatous diseaseEur J Dermatol2000 10184189
Not in our library
165.
Sillevis Smitt JH Discoid lupus erythematosus-like lesions in carriers of X-linked chronic granulomatous diseaseBr J Dermatol1990 122643650
Not in our library10.1111/j.1365-2133.1990.tb07286.x
166.
Johnston RB III Harbeck RJ Johnston RB Jr Recurrent severe infections in a girl with apparently variable expression of mosaicism for chronic granulomatous diseaseJ Pediatr1985 1065055
Not in our library10.1016/s0022-3476(85)80463-7
167.
Kragballe K Relation of monocyte and neutrophil oxidative metabolism to skin and oral lesions in carriers of chronic granulomatous diseaseClin Exp Immunol1981 43390398
Not in our library
168.
Martin-Villa JM Higher incidence of autoantibodies in X-linked chronic granulomatous disease carriers: random X-chromosome inactivation may be related to autoimmunityAutoimmunity1999 31261264
Not in our library10.3109/08916939908994071
169.
Gerba WM Chronic granulomatous disease and selective IgA deficiencyAm J Pediatr Hematol Oncol1982 4155160
Not in our library
170.
Shamsian BS Autosomal recessive chronic granulomatous disease, IgA deficiency and refractory autoimmune thrombocytopenia responding to Anti-CD20 monoclonal antibodyIran J Allergy Asthma Immunol2008 7181184
Not in our library
171.
[The NBT test in pediatrics]Recenti Prog Med1976 61219231
Not in our library
172.
Ayatollahi M A fast and easy nitroblue tetrazolium method for carrier screening and prenatal detection of chronic granulomatous diseaseArch Iran Med2006 9:335338
Not in our library
173.
Budny JL Grotke NC MacGillivray M Nitroblue tetrazolium dye reduction: diagnostic value in children with febrile illnessesN Y State J Med1976 76877881
Not in our library
174.
Crockard AD Diagnosis and carrier detection of chronic granulomatous disease in five families by flow cytometryInt Arch Allergy Immunol1997 114144152
Not in our library10.1159/000237660
175.
Elloumi HZ Holland SM Diagnostic assays for chronic granulomatous disease and other neutrophil disordersMethods Mol Biol2007 412505523
Not in our library10.1007/978-1-59745-467-4_31
176.
Emmendorffer A A fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine JImmunol Methods1990 131269275
Not in our library10.1016/0022-1759(90)90198-5
177.
Emmendorffer A Evaluation of flow cytometric methods for diagnosis of chronic granulomatous disease variants under routine laboratory conditionsCytometry1994 18147155
Not in our library10.1002/cyto.990180306
178.
Epling CL Neutrophil function screening in patients with chronic granulomatous disease by a flow cytometric methodCytometry1992 13615620
Not in our library10.1002/cyto.990130609
179.
Chien SC Rapid prenatal diagnosis of X-linked chronic granulomatous disease using a denaturing high-performance liquid chromatography (DHPLC) systemPrenat Diagn2003 2310921096
Not in our library10.1002/pd.761
180.
Klaudel-Dreszler MA Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RICInt J Hematol2009 90571575
Not in our library10.1007/s12185-009-0433-z
181.
de BM Prenatal diagnosis in a family with X-linked chronic granulomatous disease with the use of the polymerase chain reactionPrenat Diagn1992 12773777
Not in our library10.1002/pd.1970120910
182.
Johnston RB Jr Clinical aspects of chronic granulomatous diseaseCurr Opin Hematol2001 81722
Not in our library10.1097/00062752-200101000-00004
183.
lekst S Surgery and granulocyte transfusions for life-threatening infections in chronic granulomatous diseaseHelv Paediatr Acta1985 40277284
Not in our library
184.
Lekstrom-Himes JA Treatment with intralesional granulocyte instillations and interferon-gamma for a patient with chronic granulomatous disease and multiple hepatic abscessesClin Infect Dis1994 19770773
Not in our library10.1093/clinids/19.4.770
185.
Del GI Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literatureAnn Hematol2003 82189192
Not in our library10.1007/s00277-002-0590-0
186.
Bhattacharya A Successful umbilical cord blood stem cell transplantation for chronic granulomatous diseaseBone Marrow Transplant2003 31403405
Not in our library10.1038/sj.bmt.1703863
187.
Seger RA Modern management of chronic granulomatous diseaseBr J Haematol2008 140255266
Not in our library10.1111/j.1365-2141.2007.06880.x
188.
Barese CN Goebel WS Dinauer MC Gene therapy for chronic granulomatous diseaseExpert Opin Biol Ther2004 414231434
Not in our library10.1517/14712598.4.9.1423
189.
Gene therapy for X-linked chronic granulomatous diseaseHaematologica2000 85450
Not in our library
190.
Becker S Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cellsHum Gene Ther1998 %20;915611570
Not in our library10.1089/hum.1998.9.11-1561
191.
Bjorgvinsdottir H Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous diseaseBlood1997 894148
Not in our library
192.
Blaese RM What is the status of gene therapy for primary immunodeficiency?Immunol Res2007 38274284
Not in our library10.1007/s12026-007-0009-z

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.